Johnson & Johnson: Negative Alpha Likely Ahead (Archive)
Technical analysis points to JNJ underperforming the S&P 500 in coming quarters.
This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.
Elevator Pitch
- Johnson & Johnson's talc lawsuit issues continue.
- Looming loss of exclusivity on JNJ's top drug can drag revenues.
- A string of revenue and EBIT misses does not inspire confidence.
- Technical analysis suggests negative alpha ahead for JNJ relative to the S&P 500.
Read the full article here.
Disclosures and Disclaimers
Past performance ≠ future results. Not investment advice. See full Disclaimer.
Comments ()